$MAZE

Bernstein Harold sold $270K of MAZE

Bernstein Harold (President, R&D & CMO) sold 10,295 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.78–$27.12, $0.27M total) across 4 trades over 2026-09-02 to 2026-09-03.

Original reporting
SEC EDGAR · Bernstein Harold
Published Sep 4, 2026, 8:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MAZE
Bearish
medium confidence
Mentioned
$MAZE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAZEBearishLow
01

Why it matters

Insider sell of $270K by a senior executive may influence short-term sentiment.

02

Market read

Provides fresh data on insider activity for MAZE, useful for short-term traders.

03

What to watch

No 10b5-1 plan; timing may be unrelated to company fundamentals.

Relevance 4/10Novelty 3/10Timing: filing on 2026-09-04

Background

SEC Form 4 filing discloses insider transactions.

Company-level read

Ticker impact

$MAZEBearishMedium confidence
Context

President of R&D & CMO sold 10,295 shares for $270,110.80 in a Form 4 filing.

Expected impact

Potential short-term downward pressure on MAZE stock.

Evidence & confidence

The sale size is modest but involves a senior executive; markets often react negatively to insider sells.

Market effects

May raise concerns in biotech R&D leadership stability.

Limited to US biotech investors.

Low global impact.

Counterpoint

Sale could be routine portfolio diversification, not a negative signal.

Key entities

  • Bernstein Harold

    President, R&D & CMO of Maze Therapeutics

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MAZEMed

Maze Therapeutics, Inc. (MAZE): Results of Operations and Financial Condition

Maze Therapeutics, Inc. (MAZE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongo